Q-Line Biotech aims to raise over ₹214 crore through its IPO, but critics highlight concerns over its high valuation, financial stability, and limited peer comparison as it targets growth in the SME diagnostics market.
Q-Line Biotech is coming to the SME market with a public issue that values the diagnostics maker at the upper end of its price band, even as its latest earnings and leverage profile invite caution. The company develops and sells diagnostic reagents, kits, consumables and equipment for hospitals, laboratories and medical colleges, and has built its business around in-vitro diagnostics, including clinical chemistry, haematology, immunodiagnostics and molecular diagnostics.
According to the offer details tracked by Moneycontrol, the IPO opened on 21 May 2026 and closed on 25 May 2026, with shares offered in a price band of ₹326 to ₹343 and a lot size of 400 shares. The issue comprises 62.53 lakh equity shares, aiming to raise ₹214.48 crore at the top end, with proceeds earmarked for working capital, repayment of borrowings and general corporate use. ICICI Direct said the company was incorporated in 2010 and has positioned itself as a supplier of diagnostic products to a broad healthcare customer base.
The financial record shows steady revenue growth, but profit has been less consistent. The company reported consolidated income of ₹184.81 crore in FY23, ₹206.45 crore in FY24 and ₹322.58 crore in FY25, before recording ₹236.50 crore in the first nine months of FY26. Net profit moved from ₹32.10 crore in FY23 to ₹34.44 crore in FY24, then slipped to ₹28.13 crore in FY25 before rising to ₹38.69 crore in the nine months to December 2025. The review from ipowatch.in noted that the FY25 decline reflected accounting adjustments, while the strong interim profit raised questions about whether that pace can be maintained.
The balance sheet also suggests a more complex picture. As of 31 December 2025, the company had borrowings of ₹242.57 crore and contingent liabilities of ₹61.64 crore, both of which may weigh on investor sentiment. The same review said the offer was priced at 2.44 times book value based on net asset value of ₹140.81 per share as of 31 December 2025, while an implied price-to-earnings ratio would be 15.51 times on annualised FY26 earnings or 28.44 times on FY25 profit. On that basis, the issue appears fully valued rather than cheap.
There is no direct listed peer in the offer document, which makes comparison harder. The company has also not paid dividends in the periods covered by the offer papers. With a post-issue market capitalisation estimated at about ₹800.16 crore, the transaction looks aimed more at funding growth and strengthening the balance sheet than offering a clear valuation discount. For investors willing to take a longer view, the diagnostics business may still merit consideration, but the pricing leaves little room for error.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
